During a conference call with analysts on May 3, Abiomed CEO Michael R. Minogue said the company’s strategic plans would not change if shareholders and regulatory authorities approve the merger of Abbott and St. Jude Medical.

Matthew Phillips, MD, FACC, the governor the American College of Cardiology’s (ACC’s) Texas chapter from 2013 to 2016, is one renowned cardiologist who is embracing MACRA.

A long-term analysis of two prospective cohort studies of initially healthy female registered nurses found an association between the duration of rotating night shift work and a statistically significant increase in coronary heart disease risk.

Most centers that provide septal reduction therapy performed few septal myectomy and alcohol septal ablation procedures in patients with hypertrophic cardiomyopathy, according to a retrospective inpatient database analysis of U.S. hospitals. The researchers also found that low septal myectomy volume was associated with higher mortality, longer length of hospital stay and higher costs.

A model that combines cardiac rehabilitation with input from patients and their families may improve the physical and mental health of patients following their MIs, according to a randomized trial.

The FDA announced on April 29 that it had approved the first generic version of Crestor (rosuvastatin calcium), a blockbuster oral cholesterol-lowering medication.

Two journals—DNA and Cell Biology and Genetic Testing and Molecular Biomarkers—have retracted two papers that concluded a polymorphism could signal a risk factor for coronary artery disease among Chinese patients, Retraction Watch reports. 

Abbott CEO Miles White and CFO Brian Yoor discussed the future of the combined company and addressed previous rumors about the acquisition.